ZymoGenetics (ZGEN) Announces Merck Serono to Discontinue Study in Lupus Nephritis in Ongiong Phase II/III Trials
Tweet Send to a FriendGet Alerts ZGEN Hot Sheet
Trade ZGEN Now!
In a Form 8-K, ZymoGenetics (Nasdaq: ZGEN) announced that on October 27, Merck Serono announced that it was discontinuing the study in lupus nephritis in the ongoing Phase II/III systemic lupus erythematosus atacicept program. The study combining mycophenolate mofetil, corticosteroids and atacicept in patients with kidney disease had been initiated in December 2007. The observation of an increased risk for severe infection led to the discontinuation. This observation was likely the result of the underlying significant disease activity and the concomitant use of several immunosuppressive medications. The ongoing atacicept programs in generalized SLE, rheumatoid arthritis, multiple sclerosis and hematological malignancies are continuing.
ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases primarily hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections.
ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases primarily hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections.
You May Also Be Interested In
- LRAD Corp, (LRAD), Iroquois Master Fund Enter Settlement
- Clearwire (CLWR) Approves Higher Sprint (S) Bid of $3.40/Share
- Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s
Create E-mail Alert Related Categories
Corporate News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
